相关实验视频

Updated: Mar 10, 2026

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo

Published on: July 8, 2025

腺A2B受体在缺血性脑损伤中的双相调节作用及其治疗潜力

Xu Rui¹, Wang Xi², Li Mengzhu³

¹School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, No. 4655 Daxue Road, Jinan, 250355, China.

Purinergic signalling

|March 9, 2026

概括

腺氨酸A2B受体 (A2BR) 在缺血性脑损伤中表现出双重作用. 反抗剂在急性阶段提供保护,而激动剂在晚些时候提供好处,建议新的治疗策略.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
心血管研究研究心血管研究

背景情况:

缺血性脑损伤是一个主要的全球健康问题,导致严重的神经障碍和死亡率.
氨酸A2B受体 (A2BR) 是一种与G蛋白结合的受体,涉及到诸如兴奋毒性,炎症,亡和血管功能等关键过程.
新兴研究强调了A2BR在缺血性脑损伤的背景下具有依赖时间的双相作用.

研究的目的:

审查目前关于缺血性脑损伤中的腺氨酸A2B受体 (A2BR) 的研究进展.
阐明A2BR.的分子结构,表达,分布和作用机制.
讨论针对缺血性脑损伤的A2BR的药理干预和治疗前景.

主要方法:

关于在缺血性脑损伤中研究腺氨酸A2B受体 (A2BR) 的研究文献综述.
对A2BR的分子特征,表达模式和功能角色的研究分析.
检查针对A2BR的药理学策略及其结果.

主要成果:

氨酸A2B受体 (A2BR) 抗剂在缺血性脑损伤的急性阶段表现出神经保护作用.
腺氨酸A2B受体 (A2BR) 激动剂在缺血性脑损伤的后期阶段表现出抗炎和血管保护作用.
这些依赖时间的效应表明A2BR在缺血性脑损伤中具有复杂的双相作用.

结论:

向腺氨酸A2B受体 (A2BR) 为改善缺血性脑损伤患者的长期结果提供了一个有希望的治疗途径.
了解A2BR的双相,时间依赖的作用对于开发有效的治疗策略至关重要.
未来的研究应该通过利用A2BR调节来关注缺血性脑损伤的个性化治疗方法.

关键词:

腺氨酸A2B受体的受体血液-大脑屏障是什么?激发性毒性激发性毒性缺血性脑损伤是因为神经炎症是一种神经炎症.治疗中风的治疗方法

更多相关视频

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse

Published on: July 25, 2011

相关概念视频

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...